Market news

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

Biotech leader Kiniksa stock is poised to hit a new buy point after shares soared 25% in response to better-than-expected sales numbers.

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximate

These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months.

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining. But the company has a plan.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387. Speaking at a Canaccord Genuity event, Chief Operating Officer Ross Moat said

LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximatel

KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.

Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Kiniksa Pharmaceuticals International (KNSA) just raised its 2026 net product revenue guidance to a range of US$980 million to US$995 million after releasing second quarter results and updating investors on its pipeline. See our latest analysis for Kiniksa Pharmaceuticals International. The raised 2026 guidance and strong second quarter update follow a sharp move in Kiniksa Pharmaceuticals International's stock, with an 8.1x five year total shareholder return and a 92.6% year to date share...

Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income to US$25.43 million, and it raised full-year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to US$945 million. Beyond the headline growth, the company’s upgraded outlook and progress on its cardiovascular pipeline, including the Phase 3 program for KPL-387 in recurrent pericarditis, highlight...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis trea

Kiniksa Pharmaceuticals International (KNSA) reported Q2 net income Tuesday of $0.30 per diluted sha

Moby summary of Kiniksa Pharmaceuticals, Ltd.'s Q2 2026 earnings call

Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of 0.00% and +7.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

– ARCALYST® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $980 - $995 million –– KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 –– KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients –– Conference call and webcast scheduled for 8:30 am ET toda

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported strong second-quarter 2026 financial results, raised its full-year ARCALYST sales guidance, and advanced its cardiovascular pipeline with the Phase 3 launch of KPL-387 for recurrent pericarditis. Key Investor TakeawaysKiniksa increased its 2026 ARCALYST net sales guidance to $980 million-$995 million following strong prescription growth and higher patient adoption.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

American Outdoor Brands, Cimpress, National Energy, CTO Realty and Kiniksa stand out for recent price strength backed by earnings growth and estimate revisions.

LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern Time to report its second quarter 2026 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register

If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Kiniksa’s Index Additions Mean For Investors Kiniksa Pharmaceuticals International (KNSA) has been added to multiple Russell indices, including the Russell 2000 and Russell 3000. This event can reshape how institutional investors gain exposure to the stock. These index inclusions often matter because many index funds and rules based portfolios track the Russell family. This can influence trading volumes around the effective date. For Kiniksa Pharmaceuticals International, the broad...

Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.